Author’s response to reviews

Title: Efficacy of premedication with intranasal dexmedetomidine for removal of inhaled foreign bodies in children by flexible fiberoptic bronchoscopy: a randomized, double-blind, placebo-controlled clinical trial

Authors:

Yanmei Bi (1164197332@qq.com)
Yushan Ma (mayushan_123@163.com)
Juan Ni (nijuankiki@163.com)
Lan Wu (Lwu2019@163.com)

Version: 4 Date: 21 Nov 2019

Author’s response to reviews:

Dear Editors and Reviewers:

Thank you for your letter and for the reviewers’ comments concerning our manuscript entitled “Efficacy of premedication with intranasal dexmedetomidine for removal of inhaled foreign bodies in children by flexible fiberoptic bronchoscopy: a randomized, double-blind, placebo-controlled clinical trial” (ID: BANE-D-19-00086R3). Those comments are all valuable and very helpful for revising and improving our paper. We have studied comments carefully and have made correction which we hope meet with approval. The main corrections in the paper and the responds to the reviewer’s comments are as flowing:

Responds to the editor’s comments:

1. Response to comment:( Funding -- In the Funding section, please also describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.)

Response: On page 24, line 371-373. The funding agents play no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
2. Response to comment: (CONSORT -- Please include a statement within your methods section to indicate that your study adheres to CONSORT guidelines.)

Response: On page 8, line 123. We have indicated that the study adheres to CONSORT guidelines.

3. Response to comment: (Trial registration —— Please also include the name of the trial registry in the statement at the end of your Abstract.)

Response: On page 5, line 66-67. The study was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR1800017273) on July 20, 2018.

We appreciate for Editors/Reviewers’ warm work earnestly, and hope that the correction will meet with approval.

Yours sincerely,

Lan Wu